Drugs / LITGENPROSTUCEL-L
LITGENPROSTUCEL-L
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00771017 | Jul 2008 → ? | prostate cancer | Eastern Cooperative Oncology Group | Withdrawn | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LITGENPROSTUCEL-L | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108618 ↗ |
| Known as | CG8711 | “Patients receive GVAX prostate cancer vaccine (CG1940 and CG8711) intradermally (ID) on day 1.” NCT00771017 ↗ |
| Known as | Litgenprostucel-l component of gvax prostate | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108618 ↗ |
| Modality | Vaccine | “Patients receive GVAX prostate cancer vaccine (CG1940 and CG8711) intradermally (ID) on day 1.” NCT00771017 ↗ |